Is It Time to Buy This Turnaround Pharma Stock?

Life Science

Parabilis Shatters Biotech IPO Record, Stock Surges 58% in Nasdaq Debut

Life Science

The Stock Price of UnitedHealth Group Still Falls More Than 30% from Two Years Ago, and Policy Dependency Becomes a Key Investment Consideration 

Life Science

RVMD Skyrockets 285% in a Year on Historic Pancreatic Cancer Drug Breakthrough

Life Science

The iShares U.S. Pharmaceutical ETF Has Achieved a Return of Over 42% in the Past Year

Life Science

Breaking Down VKTX: 188% Upside, Pipeline Progress and Key Risks

Life Science

Market Embraces R&D Pipeline Progress, Moderna’s Stock Soars on Cancer Vaccine Prospects

Life Science

GSK Pays 40% Premium to Buy Nuvalent in Major Oncology Push

Life Science

The Economic Outlook Clouds Over, Weighing on the Market, but Two Pharmaceutical Giants May Buck the Trend

Life Science

Double Victory for Eli Lilly: Superior Weight-Loss Data & Bold Vaccine Expansion

Life Science

CVS Policy Reversal Helps Drive Eli Lilly’s Stock Price Surge

Life Science

RVMD’s Near-100% Year-To-Date Rally Sparks Valuation Debate: Has the Stock Gotten Too Pricy?

Life Science

Strong Demand for GLP-1 Drugs Drives Eli Lilly’s Leadership with New Oral Medication and Acquisitions

Life Science

Two Beaten-Down Pharma Giants: Biotech’s Cyclical Turn Delivers Prime Dip-Buy Opportunities

Life Science

Gene Editing Could Become the Next “Golden Rush” in the Pharmaceutical Industry, What Does This Mean for CRISPR Therapeutics?

Life Science